Besides Germany, clopidogrel could also obtain its marketing authorization in Luxembourg within the second quarter of 2008. Applications for approval in additional European countries are in preparation.
Antiplatelet agents such as clopidogrel inhibit the aggregation of blood platelets and are used to inhibit the formation or the growth of blood clots. In medical practice they are prescribed for the prevention and treatment of atherothrombotic events including cerebrovascular disease, coronary artery disease and peripheral vascular disease.